Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 1

2(40.0%)

Phase 3

1(20.0%)

5Total

Phase 2(2)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07519499Phase 2Not Yet Recruiting

Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 Injection

Role: lead

NCT07498634Phase 3Completed

Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS

Role: lead

NCT07070297Phase 1Completed

A Single-Arm Phase Ic Clinical Study of XKH001 Injection in Patients With Allergic Asthma After Multiple Doses

Role: lead

NCT07054736Phase 2Not Yet Recruiting

Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis

Role: lead

NCT06196762Phase 1Recruiting

Phase I of XKH002 Injection in Patients

Role: lead

All 5 trials loaded